Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 4:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,159 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fluzone Clear all
Not listed Not applicable Interventional

Effect of Educational Intervention in Patients With Low-Risk Chronic Obstructive Pulmonary Disease

NCT00932711
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Educational brochures
Behavioral
Lead sponsor
VA Midwest Health Care Network
Federal
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 3, 2009 · Synced Oct 18, 2026, 4:09 AM EDT
Not listed No phase listed Observational

National Vaccine Adverse Event Reporting Survey and Etiology

NCT05095844
View directory record Official record
Conditions
COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use, Corona Virus Infection, Blood Clot, Thrombocytopenia, Neuritis, Vasculitis, Influenza, Guillain-Barré, GWAS, Genetic Sequencing
Interventions
vaccinated
Biological
Lead sponsor
Neuroganics LLC
Industry
Eligibility
5 Years to 99 Years
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Northglenn, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of a Multilevel Intervention on Adult COVID-19 and Influenza Vaccination Rate

NCT06646406
View directory record Official record
Conditions
COVID-19 Immunisation, Influenza Vaccine
Interventions
Patient letter and clinician communication
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
19 Years and older
Enrollment
114,165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Anti-Hemagglutinin (Anti-HA) Antibodies as Protection From the Flu in Healthy People

NCT01971255
View directory record Official record
Conditions
Influenza
Interventions
Ca/04/2009/H1N1r Challenge Virus
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults

NCT00546585
View directory record Official record
Conditions
Influenza
Interventions
Influenza A/H7N7 Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Not applicable Interventional Results available

SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings

NCT06191393
View directory record Official record
Conditions
SARS-CoV-2 Infection, Influenza A, Influenza B
Interventions
Aptitude Medical Systems Metrix COVID/Flu Test
Diagnostic Test
Lead sponsor
Aptitude Medical Systems
Industry
Eligibility
2 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Trussville, Alabama • Goleta, California • Chelmsford, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years

NCT02212106
View directory record Official record
Conditions
Influenza, Human
Interventions
bioCSL Trivalent Influenza Virus Vaccine (CSL TIV), Comparator Quadrivalent Influenza Virus Vaccine
Biological
Lead sponsor
Seqirus
Industry
Eligibility
5 Years to 8 Years
Enrollment
402 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
11
States / cities
Los Angeles, California • Boise, Idaho • St Louis, Missouri + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2015 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

NCT01954251
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster vaccine GSK 1437173A, GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
829 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Phoenix, Arizona • Carnegie, Pennsylvania • Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Not applicable Interventional

Efficacy of Communication Modalities for Promoting Flu Shots

NCT05509270
View directory record Official record
Conditions
Influenza Vaccination, Health Promotion, Health Behavior, Risk Reduction
Interventions
Letter, Patient portal, SMS
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
43,225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 18, 2026, 4:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nasal Swab Home Collection Kit (NSHC Kit) Study

NCT03813966
View directory record Official record
Conditions
Influenza Viral Infections
Interventions
Sofia Influenza A+B FIA
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
0 Years and older
Enrollment
1,181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Not applicable Interventional

Adult Influenza Vaccination Text Message Reminders With Electronic Health Record Alerts

NCT02284594
View directory record Official record
Conditions
Influenza
Interventions
text message
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
4,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 18, 2026, 4:09 AM EDT
Completed No phase listed Observational

Influenza Vaccine in HIV Infection: Immune Response and Effect on Viral Load

NCT00025922
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Phase 4 Interventional Results available

Evaluating The Safety And Clinical Efficacy Of Elderberry Extract In Patients With Influenza

NCT03410862
View directory record Official record
Conditions
Influenza, Human
Interventions
Elderberry Extract, Placebos
Drug
Lead sponsor
michael macknin
Other
Eligibility
5 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects

NCT02256488
View directory record Official record
Conditions
Prophylaxis: Influenza
Interventions
TIVc_LOT A, TIVc_LOT B, TIVc_LOT C, TIVf
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,561 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
24
States / cities
Anaheim, California • Redding, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 18, 2026, 4:09 AM EDT
Recruiting Phase 3 Interventional

A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts

NCT06094010
View directory record Official record
Conditions
Influenza
Interventions
Baloxavir Marboxil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
3 Weeks to 11 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
28
States / cities
Birmingham, Alabama • Harrisburg, Arkansas • Miami, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immune Response Following Seasonal Influenza Vaccination

NCT03163342
View directory record Official record
Conditions
Influenza
Interventions
Licensed seasonal influenza vaccine
Biological
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 18, 2026, 4:09 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older

NCT00976027
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine High Dose, Trivalent inactivated influenza vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
65 Years and older
Enrollment
9,172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
96
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 86 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza

NCT00957996
View directory record Official record
Conditions
Seasonal Influenza, Cough, Sore Throat, Nasal Congestion, Myalgia, Headache, Fatigue
Interventions
Peramivir
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
79
States / cities
Dothan, Alabama • Mobile, Alabama • Jonesboro, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age

NCT06097273
View directory record Official record
Conditions
SARS-CoV-2, Influenza
Interventions
mRNA-1083, Placebo, Influenza Vaccine, COVID-19 Vaccine
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years and older
Enrollment
8,061 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
146
States / cities
Anniston, Alabama • Birmingham, Alabama • Cullman, Alabama + 122 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years

NCT01560793
View directory record Official record
Conditions
Influenza
Interventions
VAX161 [STF2.HA5 H5N1]
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Miami, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)

NCT00783926
View directory record Official record
Conditions
Influenza, Pandemic Influenza
Interventions
H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)
Biological
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
6
States / cities
Wichita, Kansas • Lexington, Kentucky • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM

NCT01011049
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine USP Trivalent Types A and B
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
44
States / cities
Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 18, 2026, 4:09 AM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly

NCT01623232
View directory record Official record
Conditions
Influenza Vaccines, Aged
Interventions
MAS-1 adjuvant and influenza HA antigen, standard dose, inactivated trivalent influenza vaccine (TIV)
Biological
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
65 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
4
States / cities
Palo Alto, California • Iowa City, Iowa • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2012 · Synced Oct 18, 2026, 4:09 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Influenza Human Challenge Model

NCT05332899
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Type A H3N2 Challenge
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 18, 2026, 4:09 AM EDT